181 related articles for article (PubMed ID: 34696348)
1. Application Route and Immune Status of the Host Determine Safety and Oncolytic Activity of Oncolytic Coxsackievirus B3 Variant PD-H.
Hazini A; Dieringer B; Klingel K; Pryshliak M; Geisler A; Kobelt D; Daberkow O; Kurreck J; Linthout SV; Fechner H
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696348
[TBL] [Abstract][Full Text] [Related]
2. Heparan Sulfate Binding Coxsackievirus B3 Strain PD: A Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma.
Hazini A; Pryshliak M; Brückner V; Klingel K; Sauter M; Pinkert S; Kurreck J; Fechner H
Hum Gene Ther; 2018 Nov; 29(11):1301-1314. PubMed ID: 29739251
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.
Lin Y; Wang W; Wan J; Yang Y; Fu W; Pan D; Cai L; Cheng T; Huang X; Wang Y
Virol J; 2018 Apr; 15(1):65. PubMed ID: 29631630
[TBL] [Abstract][Full Text] [Related]
4. miR-375- and miR-1-Regulated Coxsackievirus B3 Has No Pancreas and Heart Toxicity But Strong Antitumor Efficiency in Colorectal Carcinomas.
Hazini A; Dieringer B; Pryshliak M; Knoch KP; Heimann L; Tolksdorf B; Pappritz K; El-Shafeey M; Solimena M; Beling A; Kurreck J; Klingel K; Fechner H
Hum Gene Ther; 2021 Feb; 32(3-4):216-230. PubMed ID: 33481658
[TBL] [Abstract][Full Text] [Related]
5. Development of a new mouse model for coxsackievirus-induced myocarditis by attenuating coxsackievirus B3 virulence in the pancreas.
Pinkert S; Pryshliak M; Pappritz K; Knoch K; Hazini A; Dieringer B; Schaar K; Dong F; Hinze L; Lin J; Lassner D; Klopfleisch R; Solimena M; Tschöpe C; Kaya Z; El-Shafeey M; Beling A; Kurreck J; Van Linthout S; Klingel K; Fechner H
Cardiovasc Res; 2020 Aug; 116(10):1756-1766. PubMed ID: 31598635
[TBL] [Abstract][Full Text] [Related]
6. Fast Track Adaptation of Oncolytic Coxsackie B3 Virus to Resistant Colorectal Cancer Cells - a Method to Personalize Virotherapy.
Elsner L; Heimann L; Geisler A; Dieringer B; Knoch KP; Hinze L; Klingel K; Solimena M; Kurreck J; Fechner H
Biol Proced Online; 2024 Apr; 26(1):11. PubMed ID: 38664647
[TBL] [Abstract][Full Text] [Related]
7. Coxsackievirus B3-Its Potential as an Oncolytic Virus.
Geisler A; Hazini A; Heimann L; Kurreck J; Fechner H
Viruses; 2021 Apr; 13(5):. PubMed ID: 33919076
[TBL] [Abstract][Full Text] [Related]
8. Generation of a microRNA-Regulated Oncolytic Coxsackievirus B3.
Dieringer B; Elsner L; Hazini A; Kurreck J; Fechner H
Methods Mol Biol; 2022; 2521():259-282. PubMed ID: 35733003
[TBL] [Abstract][Full Text] [Related]
9. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma.
Miyamoto S; Inoue H; Nakamura T; Yamada M; Sakamoto C; Urata Y; Okazaki T; Marumoto T; Takahashi A; Takayama K; Nakanishi Y; Shimizu H; Tani K
Cancer Res; 2012 May; 72(10):2609-21. PubMed ID: 22461509
[TBL] [Abstract][Full Text] [Related]
10. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
[TBL] [Abstract][Full Text] [Related]
11. MiR-375-mediated suppression of engineered coxsackievirus B3 in pancreatic cells.
Pryshliak M; Hazini A; Knoch K; Dieringer B; Tolksdorf B; Solimena M; Kurreck J; Pinkert S; Fechner H
FEBS Lett; 2020 Feb; 594(4):763-775. PubMed ID: 31643074
[TBL] [Abstract][Full Text] [Related]
12. Natural Oncolysis of Enterovirus 71 in Antitumor Therapy of Colorectal Cancer.
Ruan Z; Chi J; Kong Y; Li C; Ruan X; Zhou X; Chen Y; Li Y; Luo Z
Adv Biol (Weinh); 2023 Jul; 7(7):e2200336. PubMed ID: 37132155
[TBL] [Abstract][Full Text] [Related]
13. [Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6].
Wang Q; Wang YH; Li Y; Xing M; Zhou DM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):71-76. PubMed ID: 35048603
[TBL] [Abstract][Full Text] [Related]
14. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
Bahreyni A; Liu H; Mohamud Y; Xue YC; Zhang J; Luo H
Cancer Lett; 2022 Nov; 548():215849. PubMed ID: 35995138
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of different human colorectal cancer xenografts after a single intravenous injection of oncolytic vaccinia virus GLV-1h68.
Ehrig K; Kilinc MO; Chen NG; Stritzker J; Buckel L; Zhang Q; Szalay AA
J Transl Med; 2013 Mar; 11():79. PubMed ID: 23531320
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of RNA Helicase Activity Prevents Coxsackievirus B3-Induced Myocarditis in Human iPS Cardiomyocytes.
Yun SH; Shin HH; Ju ES; Lee YJ; Lim BK; Jeon ES
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32344926
[TBL] [Abstract][Full Text] [Related]
17. Improved replication efficiency of echovirus 5 after transfection of colon cancer cells using an authentic 5' RNA genome end methodology.
Israelsson S; Sävneby A; Ekström JO; Jonsson N; Edman K; Lindberg AM
Invest New Drugs; 2014 Dec; 32(6):1063-70. PubMed ID: 25052234
[TBL] [Abstract][Full Text] [Related]
18. Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
Yanagawa B; Spiller OB; Proctor DG; Choy J; Luo H; Zhang HM; Suarez A; Yang D; McManus BM
J Infect Dis; 2004 Apr; 189(8):1431-9. PubMed ID: 15073680
[TBL] [Abstract][Full Text] [Related]
19. Cellular immune responses in mice challenged with an amyocarditic variant of Coxsackievirus B3.
Lutton CW; Gudvangen RJ; Nealon TJ; Paque RE; Gauntt CJ
J Med Virol; 1985 Dec; 17(4):345-57. PubMed ID: 3001222
[TBL] [Abstract][Full Text] [Related]
20. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
